Retrospective analysis reveals OXA-244 in E. coli indicates challenges in screening methods for CPE surveillance.
BACKGROUND: The prevalence of OXA-244-producing Enterobacterales is increasing in Europe, but their detection on screening media is limited. We assessed the proportion of OXA-244 carriage among carbapenemase-producing Enterobacterales (CPE) isolates, and specifically among OXA-48-like producers, at our hospital, addressing the challenges posed by conventional detection methods. METHODS: Patients were screened with a rectal swab. For cases with a positive polymerase chain reaction (PCR) for OXA-48 but negative culture on ChromID® CARBA SMART agar, the rectal swab was inoculated on mSuperCARBA® agar, and ChromID® CPS ELITE agar if negative. An additional ChromID® ESBL agar could also be plated and incubated. RESULTS: All patients with a CPE detection from July 2023 to July 2024 were included in the retrospective analysis. OXA-244 variant was identified in 16 cases, on the following agar plates: 13 on mSuperCARBA® (also recovered on 5 ChromID® ESBL agar), and 3 on ChromID® CPS ELITE (also recovered on 3 ChromID® ESBL agar). OXA-244 producers represented 21% of all CPE isolates and 28% of OXA-48-like producers. All isolated OXA-244 producers were Escherichia coli. CONCLUSION: OXA-244 variant poses diagnostic and surveillance challenges. Its high proportion among CPE isolates, and particularly among OXA-48-like producers, in our study suggests that this variant may be underdetected and highlights the need for adapted screening methods, with PCR prioritized for detecting OXA-244 carriers. Inadequate screening strategies can lead to undetected transmission and increase the risk of outbreaks.
No takes yet. Share an insight, caveat, or question.
Querin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: